Course Catalog
Browse our full catalog of continuing education courses and events
Browse Courses & Events
Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Montana/Wyoming
Lori A. Leslie, MD; Jack W. Erter III, MD, MMHC
Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – North Carolina
Krish Patel, MD; Tara Graff, DO, MS
Medical Crossfire®: BPDCN in 2026—Expert Perspectives on Diagnosis, Frontline Therapy, and the Evolving CD123-Directed Pipeline
July 21, 2026
Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Kansas Society of Clinical Oncology
Aditya Bardia, MD, MPH, FASCO; Bachar Samra, MD
Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Washington
Krish Patel, MD; Girish Kunapareddy, MD
Castleman Disease in Practice—Recognizing, Classifying, and Treating a Rare Disorder
July 28, 2026
Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Tennessee
Krish Patel, MD; Premila Malhotra, MD
Clinical Crossroads™: The Importance of Considering Lambert-Eaton Myasthenic Syndrome (LEMS) in the Differential Diagnosis
Katherine Ruzhansky, MD, MS; Perry Shieh, MD, PhD, FAAN
Community Practice Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer
Aditya Bardia, MD, MPH, FASCO; Kamel Abou Hussein, MD
From Chair to Care Plan—Applying Evidence to Patient-Centered Management
Walter Whitley, OD, MBA, FAAO; Cecelia Koetting, OD, FAAO, DipABO
Timing Is Everything—Onset, Duration, and Dosing in Real-World Care
Walter Whitley, OD, MBA, FAAO; Cecelia Koetting, OD, FAAO, DipABO
From Dropout to Long-Term Wear—A Case-Based Approach to Personalized Contact Lens Care
Adam Ramsey, OD; Jessilin Quint, OD, MBA, MS, FAAO
Expanding the Fit—Mastering Toric and Multifocal Success in Complex Patients
Adam Ramsey, OD; Jessilin Quint, OD, MBA, MS, FAAO
Mechanism Matters—How OTC Therapies Interrupt the Allergic Cascade
Walter Whitley, OD, MBA, FAAO; Cecelia Koetting, OD, FAAO, DipABO
Modality Matters—Optimizing Contact Lens Selection for Real-World Wear
Adam Ramsey, OD; Jessilin Quint, OD, MBA, MS, FAAO
Burst CME™ Part VI: What Does this all Mean for Patients with IgAN?
Professor Jonathan Barratt, PhD, FRCP; Richard Lafayette, MD
Burst CME™ Part V: Complement Inhibitors in IgAN
Professor Jonathan Barratt, PhD, FRCP; Richard Lafayette, MD
Burst CME™ Part IV: Anti-CD38 Therapies in IgAN
Professor Jonathan Barratt, PhD, FRCP; Richard Lafayette, MD
Burst CME™ Part III: BAFF and APRIL Directed Therapies in IgAN
Professor Jonathan Barratt, PhD, FRCP; Richard Lafayette, MD
Burst CME™ Part II: Endothelin A Receptor Antagonists in IgAN
Professor Jonathan Barratt, PhD, FRCP; Richard Lafayette, MD
Burst CME™ Part I: What’s New in IgAN?
Professor Jonathan Barratt, PhD, FRCP; Richard Lafayette, MD
Burst CME™: Elevating Care in the Management of IgA Nephropathy (IgAN) Nursing Track
Professor Jonathan Barratt, PhD, FRCP; Richard Lafayette, MD
BURST CME™ Activity 2: Oral SERD Monotherapy: Understanding the Evidence Base
Adam Brufsky, MD, PhD; Manali Bhave, MD
Project ECHO®: CAR T in Practice: Identifying Eligible Patients Across Hematologic Malignancies
Jesús G. Berdeja, MD; Michael Byrne, DO, FACP
Beyond the Itch—Decoding the Immunopathology of Allergic Conjunctivitis
Walter Whitley, OD, MBA, FAAO; Cecelia Koetting, OD, FAAO, DipABO
Cases and Conversations: Applying the Evidence – Real-World Strategies to Optimize Care for Patients With Myelofibrosis
Ruben A. Mesa, MD, FACP; Andrew Kuykendall, MD; Sangeetha Venugopal, MD, MS
Advances in™ Generalized Myasthenia Gravis: Continuing the Quest for Novel Therapies
James F. Howard Jr, MD, FAAN; Tuan Vu, MD
Cases and Conversations™: Uniting Heart and Kidney Care: Optimizing Outcomes in Cardio-Kidney-Metabolic Disorders
Katherine E. Di Palo, PharmD, MBA, MS; Nancy M. Albert, PhD, APRN-CCNS, CHFN, CCRN, NE-BC, FCCM, FAH...
BURST CME™ Activity 1: Foundations of Endocrine Resistance and Oral SERDs in HR+/HER2– Metastatic Breast Cancer
Adam Brufsky, MD, PhD; Manali Bhave, MD
Tumor Board: Optimizing NSCLC Care—Leveraging the Latest Evidence on Targeted Therapy and Immuno-Oncology
Enriqueta Felip, MD, PhD; Justin Gainor, MD; Julia Rotow, MD; Urs Weber, MD
ADCs and Bispecific Antibodies Across Solid Tumors: Integrating New Targets, New Data, and New Decisions
William J. Gradishar, MD, FASCO, FACP; Rebecca Arend, MD, MSPH; Aaron Lisberg, MD; Ulka Vaishampayan...
Show Me the Data™: Redefining Treatment Paradigms in Triple-Negative Breast Cancer Across the Disease Continuum
Hope S. Rugo, MD, FASCO; Neil M. Iyengar, MD; Heather McArthur, MD, MPH; Jason Aboudi Mouabbi, MD
Medical Crossfire®: Precision Oncology in NSCLC – Translating HER2 and TROP2 Innovation into Practice-Changing Care
Benjamin P. Levy, MD; Sarah Goldberg, MD, MPH; Jacob Sands, MD; Helena Yu, MD
The Rapidly Changing Treatment Landscape in the Management of Atopic Dermatitis—A Place in Therapy for OX40-OX40L Inhibitors
Andrew Blauvelt, MD, MBA; Melinda Gooderham, MD, FRCPC
Selecting an Optimal Therapeutic Strategy for the Management of Atopic Dermatitis in Young Children
Elaine Siegfried, MD; Lawrence F. Eichenfield, MD
PER Global Perspectives: Differentiating and Managing Toxicities with TROP2-Targeted ADCs in NSCLC Through Multidisciplinary Pathways
Solange Peters, MD, PhD; Stephanie McDonald, FNP-BC, AOCNP; Antonio Passaro, MD, PhD; Jacob Sands, M...
Oncology Town Hall: Updates From Chicago: Oral SERDs in HR+/HER2− Metastatic Breast Cancer–What the Latest Data Really Tell Us
Virginia Kaklamani, MD, DSc; Kamel Abou Hussein, MD; Javier Cortés, MD, PhD; Seth A. Wander, MD, PhD
Obesity: New and Emerging Strategies to Optimally Manage a Chronic Disease
Scott Kahan, MD, MPH; Robert F. Kushner, MD, MS, DABOM; Christopher D. Still, DO, FACP, FTOS
Cure to Cancer Survivorship: A New Era of Biomarkers, Interventions, and Care Models
February 6, 2027
Oncology Town Hall: From Evidence to Action—Applying KRAS-Targeted Advances in Solid Tumors
July 30, 2026
Hot Seat: Which Agent, and When? Integrating Next-Generation Endocrine Strategies Into HR+/HER2– Breast Cancer Management
Ruta D. Rao, MD; Kamel Abou Hussein, MD; Jame Abraham MD, FACP; Paolo Tarantino, MD, PhD
Tumor Board: Evolving Immunotherapy Strategies for Stage I-III NSCLC
Tina Cascone, MD, PhD; Puneeth Iyengar, MD, PhD; Paula A. Ugalde Figueroa, MD
Cases and Conversations: Adopting New Treatment Strategies in Polycythemia Vera and Essential Thrombocythemia
Gabriela Hobbs, MD; Rami Komrokji, MD; Douglas A. Tremblay, MD
Cases and Conversations: Optimizing Oral SERD-Based Therapy After CDK4/6 Inhibition in HR+/HER2– MBC
Virginia Kaklamani, MD, DSc; Antonio Giordano, MD, PhD; Nadia Harbeck, MD, PhD; Sarah Sammons, MD
Medical Crossfire®: Closing Clinical Practice Gaps in Hepatobiliary Cancer With Emerging Immunotherapies and Delivery Innovations
Ghassan Abou-Alfa, MD, MBA; Riad Salem, MD, MBA; Rachna Shroff, MD, MS, FASCO; Arndt Vogel, MD, PhD
Live Tumor Board: Exploring Novel Targets and Breakthrough Treatment Strategies in Extrapulmonary Neuroendocrine Carcinomas
Aman Chauhan, MD, MBBS; Jonathan Strosberg, MD; Sylvia L. Asa, MD, PhD
Practical Strategies for Monitoring and Managing Toxicities With Novel Therapies for HER2-Positive Gastroesophageal Adenocarcinoma
Samuel J. Klempner, MD, FASCO; Christian Baglini, MS, AGNP-BC; Jonathan N. Glickman, MD, PhD
Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – New York
Lori A. Leslie, MD; Bachar Samra, MD